The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis

J Heart Valve Dis. 2016 Jul;25(4):522-524.

Authors

Alberto Banzato¹, Gentian Denas², Giuseppe Lombardi³, Ardi Pambuku³, Alessandra Bianchi¹, Vittorio Pengo⁴

Affiliations

¹ Cardiology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
² Cardiology Clinic, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy. Electrronic correspondence: gentian.denas@unipd.it.
³ Medical Oncology 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
⁴ Cardiology Clinic, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padua, Italy.

PMID: 28009964

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anticoagulants / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Aortic Valve / surgery*
Bevacizumab / therapeutic use
Brain Neoplasms / drug therapy
Brain Neoplasms / secondary
Heart Valve Prosthesis*
Humans
Lung Neoplasms / pathology
Lung Neoplasms / surgery
Male
Middle Aged
Risk Factors
Thrombosis / etiology*
Thrombosis / prevention & control*

Substances

Anticoagulants
Antineoplastic Agents, Immunological
Bevacizumab